Nirmatrelvir

Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research[1].

Product Specifications

CAS Number

[2628280-40-8]

Product Name Alternative

PF-07321332

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nirmatrelvir.html

Purity

99.83

Solubility

DMSO : 140 mg/mL (ultrasonic) |Ethanol : 50 mg/mL (ultrasonic)

Smiles

O=C(NCC1)[C@@H]1C[C@@H](C#N)NC([C@@H]2[C@]3([H])[C@@](CN2C([C@H](C(C)(C)C)NC(C(F)(F)F)=O)=O)([H])C3(C)C)=O

Molecular Formula

C23H32F3N5O4

Molecular Weight

499.53

Precautions

H315, H319, H335

References & Citations

[1]KoenVandyck, et al. Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection. Current Opinion in Virology Available online 27 April 2021